Inhibikase Therapeutics Inc

-

Stock Issuer and Owners

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Inhibikase Therapeutics Inc
TickerIKT
CIK #0001750149
CUSIP45719W106
SectorLife Sciences - Biological Products, (No Disgnostic Substances)
Address3350 Riverwood Parkway Se, Suite 1900, Atlanta, GA 30339
Source [EDGAR]
Reg D Offering (Form D) Filed Raised Terms
Inhibikase Therapeutics Inc 2024-06-04 Exemption: 506(b) · Remaining: $7,999,999 · Duration: One year or less · Commission: $339,994 · Revenue: Decline to Disclose
CIK Filing 2011 - 2026
[0001750149] 10-K
[0001750149] 10-Q
[0001750149] 3
[0001750149] 4
[0001750149] 8-K
[0001750149] D
[0001750149] SC 13D
[0001750149] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
RA Capital Management LP Inhibikase Therapeutics Inc [2026-07-17] 0.0
Trails Edge Capital Partners LP Inhibikase Therapeutics Inc [2025-12-31] 0.0
ADAR1 Capital Management LLC Inhibikase Therapeutics Inc [2025-02-14] 0.0
Nantahala Capital Management LLC Inhibikase Therapeutics Inc [2025-02-14] 0.0
Armistice Capital LLC Inhibikase Therapeutics Inc [2024-11-14] 0.99
Soleus Private Equity Fund III LP Inhibikase Therapeutics Inc [2024-10-28] 0.99
SP IKT Holdings LLC Inhibikase Therapeutics Inc [2024-10-28] 81948.69
Sands Capital Life Sciences Pulse Fund II LP Inhibikase Therapeutics Inc [2024-10-25] 819416.3
Perceptive Advisors LLC Inhibikase Therapeutics Inc [2024-10-22] 81949.99
Fairmount Funds Management LLC Inhibikase Therapeutics Inc [2024-10-17] 0.9
Commodore Capital LP Inhibikase Therapeutics Inc [2024-10-17] 0.99
Point72 Asset Management LP Inhibikase Therapeutics Inc [2024-10-10] 8.4
Fivet Investment Management Ltd Inhibikase Therapeutics Inc [2023-02-24] 4.78
Fivet Investment Management Ltd Inhibikase Therapeutics Inc [2023-01-31] 4.12
Fivet Investment Management Ltd Inhibikase Therapeutics Inc [2022-01-11] 6.03
Fivet Investment Management Ltd Inhibikase Therapeutics Inc [2021-12-15] 4.97
Fivet Investment Management Ltd Inhibikase Therapeutics Inc [2021-06-21] 5.83
Kalman Daniel Inhibikase Therapeutics Inc [2021-03-23] 14.8
Werner Milton H Inhibikase Therapeutics Inc [2021-02-11] 53.1
Form 3/4/5 Filer 2011 - 2026
Inhibikase Therapeutics Inc
Aurentz Vincent
Munshi Amit
Berman Dennis N
Canner David
Kush Arvind
Bellini Roberto
Cabell Christopher
McIntyre David
Iwicki Mark T
Sands Capital Life Sciences Pulse Fund II LP
Sands Capital Alternatives LLC
Sands Frank M
Freeman Roy Lester
Werner Milton H
Lees-Rolfe Garth
Grint Paul C
Dion Gisele
Frattaroli Joseph
O'Farrell Elizabeth G
Kalman Daniel
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Aurentz Vincent
Common Stock
2026-02-21 Disposed to issuer 255,299 $0.00
Munshi Amit
Common Stock
2026-02-21 Disposed to issuer 19,089 $0.00
Cabell Christopher
Common Stock
2026-02-21 Disposed to issuer 338,282 $0.00
Iwicki Mark T
Stock Option (Right to Buy) · derivative
2026-01-05 Grant 4,982,706 $0.00
McIntyre David
Stock Option (Right to Buy) · derivative
2026-01-05 Grant 986,319 $0.00
Cabell Christopher
Stock Option (Right to Buy) · derivative
2026-01-05 Grant 900,117 $0.00
Sands Capital Life Sciences Pulse Fund II LP +2
Common Stock
2025-11-21 Buy 2,068,965 $1.45 2,999,999
Munshi Amit
Stock Option (Right to Buy) · derivative
2025-06-30 Grant 108,176 $0.00
Canner David
Stock Option (Right to Buy) · derivative
2025-06-30 Grant 108,176 $0.00
Aurentz Vincent
Stock Option (Right to Buy) · derivative
2025-06-30 Grant 108,176 $0.00
Kush Arvind
Stock Option (Right to Buy) · derivative
2025-06-30 Grant 108,176 $0.00
Bellini Roberto
Stock Option (Right to Buy) · derivative
2025-06-30 Grant 108,176 $0.00
Berman Dennis N
Stock Option (Right to Buy) · derivative
2025-06-30 Grant 108,176 $0.00
McIntyre David
Stock Option (Right to Buy) · derivative
2025-04-14 Grant 1,775,539 $0.00
Cabell Christopher
Stock Option (Right to Buy) · derivative
2025-02-21 Grant 1,100,705 $0.00
Iwicki Mark T
Stock Option (Right to Buy) · derivative
2025-02-21 Grant 602,346 $0.00
Common Stock
2025-02-21 Grant 57,265 $0.00
Stock Option (Right to Buy) · derivative
2025-02-21 Grant 1,100,705 $0.00
Stock Option (Right to Buy) · derivative
2025-02-21 Grant 602,346 $0.00
Stock Option (Right to Buy) · derivative
2025-02-21 Grant 134,427 $0.00
showing 20 of 152 most recent transactions
13F Ownership Over TimeHoldersShares Held
2026-03-31 104 117,816,841
2025-12-31 74 106,415,335
2025-09-30 54 55,014,727
2025-06-30 49 54,516,967
2025-03-31 48 51,462,756
2024-12-31 32 50,027,780
2024-09-30 12 860,232
2024-06-30 13 836,496
2024-03-31 13 208,892
2023-12-31 12 236,671
2023-09-30 13 412,996
2023-06-30 15 760,940
Form 13F Holdings
Firm Period DFND Voting Shares
Wealth Enhancement Advisory Services LLC [2026-06-30] SOLE 325 18,759
True Wealth Design LLC [2026-06-30] SOLE 0 499
Farther Finance Advisors LLC [2026-06-30] SOLE 0 370
IFP Advisors LLC [2026-06-30] SOLE 23 23
Prev | Page 1 | Next
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com